Catalyst Pharmaceuticals Introduces New Corporate Website

CORAL GABLES, Fla., April 24, 2018 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today is pleased to announce the launch of its new and refreshed corporate website. This redesigned site offers quick and easy access to essential information and features, while offering a more comprehensive understanding of our company and its mission statement.

The new website (www.catalystpharma.com) has a clean modern design, greater functionality and improved rich content that reflects the vitality of our company, the passion of our employees and the richness of our goal to provide FDA approved therapies to patients suffering from various rare neuromuscular and neurological diseases.

The structure of the website and its content have been completely revised and reconstructed on the basis of best practice in order to improve accessibility. The new website also incorporates the principles of responsible web design, creating a viewing environment that supports a diverse range of users and stakeholders, including patients, physicians, shareholders and community on not only PCs, but also other devices such as smartphones.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. Firdapse® (amifampridine phosphate) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.

Catalyst is also developing CPP-115 to treat refractory infantile spasms. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission.  In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2017 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Investor Contact
Brian Korb
Solebury Trout 
(646) 378-2923
[email protected]

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
[email protected]

Media Contact
David Schull
Russo Partners
(212) 845-4271
[email protected]